JP6703483B2 - ニューレグリン調合剤の処方 - Google Patents

ニューレグリン調合剤の処方 Download PDF

Info

Publication number
JP6703483B2
JP6703483B2 JP2016544419A JP2016544419A JP6703483B2 JP 6703483 B2 JP6703483 B2 JP 6703483B2 JP 2016544419 A JP2016544419 A JP 2016544419A JP 2016544419 A JP2016544419 A JP 2016544419A JP 6703483 B2 JP6703483 B2 JP 6703483B2
Authority
JP
Japan
Prior art keywords
formulation
concentration
nrg
polypeptide
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016544419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502969A (ja
Inventor
ズホウ ミングドング
ズホウ ミングドング
Original Assignee
ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53493186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6703483(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．, ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． filed Critical ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
Publication of JP2017502969A publication Critical patent/JP2017502969A/ja
Application granted granted Critical
Publication of JP6703483B2 publication Critical patent/JP6703483B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2016544419A 2014-01-03 2014-12-17 ニューレグリン調合剤の処方 Active JP6703483B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410002665.6 2014-01-03
CN201410002665.6A CN104758922A (zh) 2014-01-03 2014-01-03 纽兰格林制剂的配方
PCT/CN2014/094073 WO2015101182A1 (zh) 2014-01-03 2014-12-17 纽兰格林制剂的配方

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020082456A Division JP7100083B2 (ja) 2014-01-03 2020-05-08 ニューレグリン調合剤の処方

Publications (2)

Publication Number Publication Date
JP2017502969A JP2017502969A (ja) 2017-01-26
JP6703483B2 true JP6703483B2 (ja) 2020-06-03

Family

ID=53493186

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016544419A Active JP6703483B2 (ja) 2014-01-03 2014-12-17 ニューレグリン調合剤の処方
JP2020082456A Active JP7100083B2 (ja) 2014-01-03 2020-05-08 ニューレグリン調合剤の処方
JP2022105452A Active JP7479068B2 (ja) 2014-01-03 2022-06-30 ニューレグリン調合剤の処方
JP2024066182A Pending JP2024099628A (ja) 2014-01-03 2024-04-16 ニューレグリン調合剤の処方

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020082456A Active JP7100083B2 (ja) 2014-01-03 2020-05-08 ニューレグリン調合剤の処方
JP2022105452A Active JP7479068B2 (ja) 2014-01-03 2022-06-30 ニューレグリン調合剤の処方
JP2024066182A Pending JP2024099628A (ja) 2014-01-03 2024-04-16 ニューレグリン調合剤の処方

Country Status (10)

Country Link
US (3) US10702585B2 (https=)
EP (2) EP3821904B1 (https=)
JP (4) JP6703483B2 (https=)
KR (3) KR20160105443A (https=)
CN (4) CN110946993A (https=)
AU (1) AU2014375637A1 (https=)
BR (1) BR112016015660A2 (https=)
CA (1) CA2935607A1 (https=)
RU (1) RU2738158C2 (https=)
WO (1) WO2015101182A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020143101A (ja) * 2014-01-03 2020-09-10 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリン調合剤の処方

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2530526T3 (es) 2005-12-30 2015-03-03 Zensun Shanghai Science And Technology Ltd Liberación extendida de neurregulina para mejorar la función cardíaca
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
KR102083046B1 (ko) 2012-06-07 2020-02-28 칠드런＇스 하스피틀 로스 앤젤레스 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법
AU2012392119B2 (en) 2012-10-08 2018-07-26 Zensun (Shanghai) Science & Technology, Co. Ltd. Compositions and methods for treating heart failure in diabetic patients
EP3895724B1 (en) 2013-05-22 2025-06-25 Zensun (Shanghai) Science and Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
FI3774859T3 (fi) 2018-04-11 2024-05-24 Salubris Biotherapeutics Inc Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
JP2022547335A (ja) * 2019-09-16 2022-11-11 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． 組換えヒトニューレグリン誘導体及びその使用
JP7425459B2 (ja) * 2019-10-11 2024-01-31 株式会社シノテスト 安定化されたｈｍｇｂ１含有溶液
CA3159894A1 (en) * 2019-12-16 2021-06-24 Seagen Inc. High performance liquid chromatography quantification of excipients

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001489A1 (en) 1987-08-10 1989-02-23 Commonwealth Scientific And Industrial Research Or Control of angiogenesis and compositions and methods therefor
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US6750196B1 (en) 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US6387638B1 (en) 1997-02-10 2002-05-14 Genentech, Inc. Heregulin variants
AU745324B2 (en) 1997-10-14 2002-03-21 Cenes Pharmaceuticals, Inc. Therapeutic methods comprising use of a neuregulin
US6054261A (en) 1998-05-20 2000-04-25 Q-Pharma, Inc. Coenzyme Q10 compositions for organ protection during perfusion
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
AU2001241839A1 (en) 2000-02-28 2001-09-12 Decode Genetics Ehf Human schizophrenia gene
AU2001274947B2 (en) 2000-05-23 2006-08-17 Acorda Therapeutics, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US7375185B2 (en) 2000-09-12 2008-05-20 The United States Of America As Represented By The Department Of Health And Human Services Cardiac myosin light chain kinase polypeptide, encoding nucleic acid, and methods of use
US6482624B2 (en) 2000-11-14 2002-11-19 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
RU2180843C1 (ru) 2001-02-19 2002-03-27 Новокузнецкий государственный институт усовершенствования врачей Способ профилактики повторного инфаркта миокарда
DE10124387A1 (de) * 2001-05-18 2002-11-28 Basf Ag Hydrophob modifizierte Polyethylenimine und Polyvinylamine zur Antiknitterausrüstung von cellulosehaltigen Textilien
CN1498656A (zh) 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
AU2003293124A1 (en) 2002-11-27 2004-06-23 Artesian Therapeutics, Inc. Heart failure gene determination and therapeutic screening
JP2007505158A (ja) 2003-05-21 2007-03-08 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 心肥大および心不全の処置としてのプロテインキナーゼＣ−μ（ＰＫＤ）の阻害
GB0413005D0 (en) 2004-06-11 2004-07-14 Coletica Ligand
WO2006108208A1 (en) 2004-10-14 2006-10-19 Adventures Plus Pty Ltd A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals
US20060160062A1 (en) 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
DE602006017071D1 (de) * 2005-01-25 2010-11-04 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
US20070141548A1 (en) 2005-03-11 2007-06-21 Jorg Kohl Organ transplant solutions and method for transplanting organs
CN100361709C (zh) 2005-08-30 2008-01-16 山东省生物药物研究院 一种对生命活性物质有保护作用的糖类组合
CN1768859A (zh) 2005-10-24 2006-05-10 天津大学 基于醛基的微粒表面多重生物功能因子组装方法
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
ES2530526T3 (es) 2005-12-30 2015-03-03 Zensun Shanghai Science And Technology Ltd Liberación extendida de neurregulina para mejorar la función cardíaca
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
ATE502998T1 (de) * 2006-07-07 2011-04-15 Procter & Gamble Waschmittelzusammensetzungen
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
CN106908603B (zh) 2007-01-25 2019-04-02 霍夫曼-拉罗奇有限公司 Igfbp-7在心力衰竭评估中的用途
CN101310779A (zh) 2007-05-25 2008-11-26 上海泽生科技开发有限公司 包含神经调节蛋白的装置及药物制剂
CN101310766B (zh) 2007-05-25 2014-04-16 上海泽生科技开发有限公司 神经调节蛋白的新用途
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
US20110212108A1 (en) 2008-05-09 2011-09-01 The Regents Of The University Of California Neuregulin/erbb signaling and integrin
US20110166068A1 (en) 2008-07-17 2011-07-07 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
EP2370458B1 (en) 2008-11-28 2014-10-15 Zensun (Shanghai) Science and Technology Limited Neuregulin peptides and their use
EP2370093A4 (en) 2008-11-28 2012-08-29 Zensun Shanghai Science And Technology Ltd NEUREGULIN AND CARDIAC STEM CELLS
ES2748886T3 (es) 2009-06-09 2020-03-18 Zensun Shanghai Science & Tech Co Ltd Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
ES2575125T3 (es) 2009-06-09 2016-06-24 Zensun (Shanghai) Science And Technology Limited Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
ES2637072T3 (es) 2010-03-10 2017-10-10 Cempra Pharmaceuticals, Inc. Formulación parenteral de antibióticos macrólidos
WO2011119836A1 (en) 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
JP2013532661A (ja) 2010-07-22 2013-08-19 リベン ファーマシューティカルズ インコーポレイテッド 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法
CN102230084B (zh) * 2011-06-14 2013-01-23 东北大学 低品位含砷难浸金矿的包覆生物氧化预处理方法
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
AU2012392119B2 (en) 2012-10-08 2018-07-26 Zensun (Shanghai) Science & Technology, Co. Ltd. Compositions and methods for treating heart failure in diabetic patients
JP6542678B2 (ja) * 2013-03-06 2019-07-10 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法
EP3895724B1 (en) 2013-05-22 2025-06-25 Zensun (Shanghai) Science and Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN104337813A (zh) 2013-07-23 2015-02-11 上海泽生科技开发有限公司 使用维生素b组合物促进胃肠系统动力的方法
CN104758300A (zh) 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020143101A (ja) * 2014-01-03 2020-09-10 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリン調合剤の処方
JP7100083B2 (ja) 2014-01-03 2022-07-12 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリン調合剤の処方

Also Published As

Publication number Publication date
EP3090756B2 (en) 2024-09-25
JP2024099628A (ja) 2024-07-25
KR20230054749A (ko) 2023-04-25
CN111012898A (zh) 2020-04-17
CN104758922A (zh) 2015-07-08
US20170007671A1 (en) 2017-01-12
JP2017502969A (ja) 2017-01-26
KR20220093387A (ko) 2022-07-05
EP3821904B1 (en) 2025-02-05
KR20160105443A (ko) 2016-09-06
CN105960248A (zh) 2016-09-21
US11969458B2 (en) 2024-04-30
JP2020143101A (ja) 2020-09-10
EP3090756A1 (en) 2016-11-09
EP3090756A4 (en) 2017-07-19
WO2015101182A1 (zh) 2015-07-09
CA2935607A1 (en) 2015-07-09
US10702585B2 (en) 2020-07-07
EP3090756B1 (en) 2020-09-30
RU2016131667A (ru) 2018-02-08
EP3821904A1 (en) 2021-05-19
US20250073306A1 (en) 2025-03-06
RU2016131667A3 (https=) 2018-08-21
JP7100083B2 (ja) 2022-07-12
JP2022130627A (ja) 2022-09-06
CN110946993A (zh) 2020-04-03
RU2738158C2 (ru) 2020-12-08
KR102522140B1 (ko) 2023-04-17
US20210113661A1 (en) 2021-04-22
JP7479068B2 (ja) 2024-05-08
AU2014375637A1 (en) 2016-07-14
BR112016015660A2 (pt) 2017-10-24

Similar Documents

Publication Publication Date Title
JP7479068B2 (ja) ニューレグリン調合剤の処方
CN102232084B (zh) 纽兰格林及其用途
CN102573792B (zh) 稳定化的液体和冻干的adamts13制剂
JP2020143166A (ja) 凍結乾燥した組換え型ｖｗｆ製剤
JP2016164199A (ja) 組換え型ｖｗｆ製剤
CN109276705B (zh) 治疗糖尿病患者心力衰竭的组份和方法
JP7832245B2 (ja) 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物
JP2026062640A (ja) ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物
US7754686B2 (en) Stabilized FGF formulations containing reducing agents
WO2018148573A1 (en) Collagen-binding agent compositions and methods of using the same
WO2020160460A1 (en) Methods of prophylactic treatment using recombinant vwf (rvwf)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200414

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200508

R150 Certificate of patent or registration of utility model

Ref document number: 6703483

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250